These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 24772857)

  • 1. [Individualization of antiviral treatment of chronic hepatitis].
    Konstantinov DIu; Konstantinova EA; Strebkova EA; Popova LL; Suzdal'tsev AA
    Eksp Klin Gastroenterol; 2013; (6):29-34. PubMed ID: 24772857
    [No Abstract]   [Full Text] [Related]  

  • 2. [Antiviral therapy of patients with chronic hepatitis C with normal level of aminotransferases].
    Lopukhova NL
    Eksp Klin Gastroenterol; 2007; (4):146-52. PubMed ID: 18409502
    [No Abstract]   [Full Text] [Related]  

  • 3. [Predictive value of virological response on sustained virological response in hepatitis C patients].
    Zhou YQ; Wang XH; Fan Y; Zhu Y; Tan WT; Mao Q
    Zhonghua Gan Zang Bing Za Zhi; 2009 Dec; 17(12):944-6. PubMed ID: 20038340
    [No Abstract]   [Full Text] [Related]  

  • 4. ADVANCE study begins enrollment.
    AIDS Patient Care STDS; 2008 Apr; 22(4):345. PubMed ID: 18422463
    [No Abstract]   [Full Text] [Related]  

  • 5. A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection.
    Suzuki F; Toyota J; Ikeda K; Chayama K; Mochida S; Hayashi N; Ishikawa H; Miyagoshi H; Hu W; McPhee F; Hughes EA; Kumada H
    Antivir Ther; 2014; 19(5):491-9. PubMed ID: 24451122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection.
    Lagging M; Langeland N; Pedersen C; Färkkilä M; Buhl MR; Mørch K; Dhillon AP; Alsiö A; Hellstrand K; Westin J; Christensen P; Leutscher P; Norkrans G;
    Hepatology; 2008 Aug; 48(2):695. PubMed ID: 18666232
    [No Abstract]   [Full Text] [Related]  

  • 7. Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases.
    Iacob S; Gheorghe L; Hrehoret D; Becheanu G; Herlea V; Popescu I
    J Gastrointestin Liver Dis; 2008 Jun; 17(2):165-72. PubMed ID: 18568137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapy of chronic Hepatitis C in 2008].
    Niederau C; Kaden T
    MMW Fortschr Med; 2008 Mar; 150(13):31-4. PubMed ID: 18522354
    [No Abstract]   [Full Text] [Related]  

  • 9. [Effectiveness and safety of antiviral therapy of military personnel suffering from chronic hepatitis C].
    Zhdanov KV; Gusev DA; Kozlov KV; Shishkin MK; Sukachev VS; Shakhmanov DM; Zhabrov SS
    Voen Med Zh; 2015 Apr; 336(4):44-9. PubMed ID: 26454938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A modified ribavirin-free interferon therapy with boceprevir in post-liver transplant recurrent hepatitis C.
    Maticic M; Luznik Z; Stepec S; Popovic P; Snedec N; Poljak M; Stanisavljevic D
    J Clin Gastroenterol; 2014; 48(5):464-5. PubMed ID: 24275712
    [No Abstract]   [Full Text] [Related]  

  • 11. [Advance in the management of the difficult-to-treat patients with chronic hepatitis C].
    Xie Y; Li MH
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):484-6. PubMed ID: 19912677
    [No Abstract]   [Full Text] [Related]  

  • 12. Impact of sex on virologic response rates in genotype 1 chronic hepatitis C patients with peginterferon alpha-2a and ribavirin treatment.
    Yu JW; Sun LJ; Zhao YH; Kang P; Yan BZ
    Int J Infect Dis; 2011 Nov; 15(11):e740-6. PubMed ID: 21803628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double filtration plasmapheresis could induce a favorable immune response for chronic hepatitis C therapy.
    Kondo Y; Ueno Y; Shimosegawa T
    Ther Apher Dial; 2012 Oct; 16(5):478-9. PubMed ID: 23046374
    [No Abstract]   [Full Text] [Related]  

  • 14. Summaries for patients. Pegylated interferon with or without ribavirin for patients with hepatitis C receiving hemodialysis.
    Ann Intern Med; 2013 Dec; 159(11):I-14. PubMed ID: 24297207
    [No Abstract]   [Full Text] [Related]  

  • 15. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
    Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
    Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load.
    Toyoda H; Kumada T; Tada T; Arakawa T; Hayashi K; Honda T; Katano Y; Goto H
    J Gastroenterol Hepatol; 2010 Jun; 25(6):1072-8. PubMed ID: 20594221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ribavirin in chronic hepatitis C: past and future.
    Loustaud-Ratti V; Rousseau A; Marquet P; Denis F; Alain S
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):249-53. PubMed ID: 19344238
    [No Abstract]   [Full Text] [Related]  

  • 18. [Prediction of sustained viral response to combinational therapy with interferon and ribavirin in chronic hepatitis C by rapid viral response].
    Li MH; Chen LJ; Qiu GH; Lu Y; Xie Y; Xu DZ
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):497-500. PubMed ID: 19912682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.
    Dore GJ; Lawitz E; Hézode C; Shafran SD; Ramji A; Tatum HA; Taliani G; Tran A; Brunetto MR; Zaltron S; Strasser SI; Weis N; Ghesquiere W; Lee SS; Larrey D; Pol S; Harley H; George J; Fung SK; de Lédinghen V; Hagens P; McPhee F; Hernandez D; Cohen D; Cooney E; Noviello S; Hughes EA
    Gastroenterology; 2015 Feb; 148(2):355-366.e1. PubMed ID: 25311593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegylated interferon treatment in HCV genotype 2 and 3 patients refractory to conventional interferon.
    Aziz S
    J Coll Physicians Surg Pak; 2012 Oct; 22(10):615-6. PubMed ID: 23058141
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.